Abstract
Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and to a lesser extent with aspergillosis. Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / therapeutic use
-
Animals
-
Antifungal Agents / therapeutic use
-
Aspergillosis / drug therapy*
-
Aspergillus fumigatus / drug effects
-
Aspergillus fumigatus / pathogenicity
-
Disease Models, Animal
-
Echinocandins / therapeutic use*
-
Iron Chelating Agents / therapeutic use*
-
Lipopeptides / therapeutic use
-
Micafungin
-
Mice
-
Mice, Inbred BALB C
-
Mucormycosis / drug therapy*
-
Polyenes / therapeutic use*
-
Rhizopus / drug effects
-
Rhizopus / pathogenicity
Substances
-
Antifungal Agents
-
Echinocandins
-
Iron Chelating Agents
-
Lipopeptides
-
Polyenes
-
liposomal amphotericin B
-
Amphotericin B
-
Micafungin